Login Register Cart 0
Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Marijuana Use in Young Adults: What Do We Know?

Author(s): Michael Wenzinger* and Fayola Fears

Volume 9, Issue 2, 2020

Page: [103 - 114] Pages: 12

DOI: 10.2174/2211556009999200414153806

Price: $65

Abstract

Cannabis is the most commonly used illicit drug in the United States. Over the past decade its use has increased, with young adults/college aged individuals having the highest proportion of users compared to any other age group. Given the high rates of usage in this age group, cannabis use is an important aspect of mental and physical health in collegeaged adults. Current evidence indicates that marijuana use, especially early and dosedependent use, can have significant negative ramifications on general functioning, academic performance, psychiatric wellness, and may be causally related to development of other substance use disorders and risky behaviors. No strong evidence supports marijuana as a beneficial treatment for any psychiatric indication, however there is evidence supporting the use of cannabidiol (CBD) in illnesses such as epilepsy. Providers must be well apprised of the current evidence base for both detecting and treating marijuana use disorder given its increasing prevalence and decreasing perception of risk. Screening of cannabis use disorder and treatment with appropriate therapy is highly important for college mental health.

Keywords: Cannabidiol (CBD), cannabis, college mental health, marijuana, psychosis, young adults, Δ9- Tetrahydrocannabinol (THC).

Graphical Abstract

[1]
Pertwee R G. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147(Suppl 1): S163-s171.
[http://dx.doi.org/10.1038/sj.bjp.0706406]
[2]
Thomas SP. Complexities emanating from legalization of marijuana. Issues Ment Health Nurs 2015; 36(9): 657-8.
[http://dx.doi.org/10.3109/01612840.2015.1075822] [PMID: 26440867]
[3]
Ammerman S, Tau G. Weeding out the truth: adolescents and cannabis. J Addict Med 2016; 10(2): 75-82.
[http://dx.doi.org/10.1097/ADM.0000000000000199] [PMID: 26985645]
[4]
US Department of Justice Drug Enforcement Administration Diversion Control Division Controlled Substances Schedules Available from: https://www. deadiversion.usdoj.gov/schedules/
[5]
substance abuse and mental health services administration. key substance use and mental health indicators in the united states: results from the 2018 national survey on drug use and health (hhs publication no. pep195068, nsduh series h54). rockville, md: center for behavioral health statistics and quality, substance abuse and mental health services administration 2019. retrieved from: http://www. samhsa.gov/data
[6]
Cerdá M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend 2012; 120(1-3): 22-7.
[http://dx.doi.org/10.1016/j.drugalcdep.2011.06.011] [PMID: 22099393]
[7]
White HR, Labouvie EW, Papadaratsakis V. Changes in substance use during the transition to adulthood: A comparison of college students and their noncollege age peers. J Drug Issues 2005; 35(2): 281-306.
[http://dx.doi.org/10.1177/002204260503500204]
[8]
American college health association american college health association-national college health assessment ii: reference group executive summary spring 2018. Silver Spring, MD: American College Health Association 2018.
[9]
Arria AM, Garnier-Dykstra LM, Caldeira KM, Vincent KB, Winick ER, O’Grady KE. Drug use patterns and continuous enrollment in college: results from a longitudinal study. J Stud Alcohol Drugs 2013; 74(1): 71-83.
[http://dx.doi.org/10.15288/jsad.2013.74.71] [PMID: 23200152]
[10]
Patrick ME, Wightman P, Schoeni RF, Schulenberg JE. Socioeconomic status and substance use among young adults: a comparison across constructs and drugs. J Stud Alcohol Drugs 2012; 73(5): 772-82.
[http://dx.doi.org/10.15288/jsad.2012.73.772] [PMID: 22846241]
[11]
Wu LT, Zhu H, Swartz MS. Trends in cannabis use disorders among racial/ethnic population groups in the United States. Drug Alcohol Depend 2016; 165: 181-90.
[http://dx.doi.org/10.1016/j.drugalcdep.2016.06.002] [PMID: 27317045]
[12]
Johnson RM, Fairman B, Gilreath T, et al. Past 15-year trends in adolescent marijuana use: differences by race/ethnicity and sex. Drug Alcohol Depend 2015; 155: 8-15.
[http://dx.doi.org/10.1016/j.drugalcdep.2015.08.025] [PMID: 26361714]
[13]
Herron A, Brennan TK. The ASAM essentials of addiction medicine. Netherlands: Wolters Kluwer Health 2019.
[14]
Barrus DG, Capogrossi KL, Cates SC, et al. Tasty THC: promises and challenges of cannabis edibles Methods Rep. (RTI Press) 2016 2016.
[http://dx.doi.org/10.3768/rtipress.2016.op.0035.1611]
[15]
Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10(2): 171-80.
[http://dx.doi.org/10.1080/13556210500123217] [PMID: 16191670]
[16]
Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 2017; 112(12): 2167-77.
[http://dx.doi.org/10.1111/add.13886] [PMID: 28556310]
[17]
Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000-2014. NCHS Data Brief 2016; (232): 1-8.
[PMID: 26828319]
[18]
Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol 2015; 213(6): 761-78.
[http://dx.doi.org/10.1016/j.ajog.2015.05.025] [PMID: 25986032]
[19]
Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109(40): E2657-64.
[http://dx.doi.org/10.1073/pnas.1206820109] [PMID: 22927402]
[20]
Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl) 1976; 49(1): 79-84.
[PMID: 822452]
[21]
Martinez JA, Roth MG, Johnson DN, Jones JA. How robustly does cannabis use associate to college grades? Findings from two cohorts. J Drug Educ 2015; 45(1): 56-67.
[http://dx.doi.org/10.1177/0047237915596606] [PMID: 26224748]
[22]
Caldeira KM, Arria AM, O’Grady KE, Vincent KB, Wish ED. The occurrence of cannabis use disorders and other cannabis-related problems among first-year college students. Addict Behav 2008; 33(3): 397-411.
[http://dx.doi.org/10.1016/j.addbeh.2007.10.001] [PMID: 18031940]
[23]
Tarter RE, Vanyukov M, Kirisci L, Reynolds M, Clark DB. Predictors of marijuana use in adolescents before and after licit drug use: examination of the gateway hypothesis. Am J Psychiatry 2006; 163(12): 2134-40.
[http://dx.doi.org/10.1176/ajp.2006.163.12.2134] [PMID: 17151165]
[24]
Schierenbeck T, Riemann D, Berger M, Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev 2008; 12(5): 381-9.
[http://dx.doi.org/10.1016/j.smrv.2007.12.004] [PMID: 18313952]
[25]
Barratt ES, Beaver W, White R. The effects of marijuana on human sleep patterns. Biol Psychiatry 1974; 8(1): 47-54.
[PMID: 4361028]
[26]
Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep 2008; 31(6): 901-8.
[http://dx.doi.org/10.1093/sleep/31.6.901] [PMID: 18548836]
[27]
D’Souza DC, Radhakrishnan R, Sherif M, et al. Cannabinoids and psychosis. Curr Pharm Des 2016; 22(42): 6380-91.
[http://dx.doi.org/10.2174/1381612822666160826105628] [PMID: 27568729]
[28]
McHugh M J. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med 2017; 47(4): 616-26.
[http://dx.doi.org/10.1017/S0033291716002671]
[29]
Renard J, Krebs MO, Le Pen G, Jay TM. Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Front Neurosci 2014; 8: 361.
[http://dx.doi.org/10.3389/fnins.2014.00361] [PMID: 25426017]
[30]
Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet jul 2007; 28370(9584): 319-2.
[http://dx.doi.org/10.1016/S0140-6736(07)61162-3]
[31]
Rusby JC, Westling E, Crowley R, Mills KL, Light JM. Associations between marijuana use and anxious mood lability during adolescence. Addict Behav 2019; 92: 89-94.
[http://dx.doi.org/10.1016/j.addbeh.2018.12.029] [PMID: 30597336]
[32]
Bonn-Miller MO, Zvolensky MJ, Bernstein A. Marijuana use motives: concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers. Addict Behav 2007; 32(1): 49-62.
[http://dx.doi.org/10.1016/j.addbeh.2006.03.018] [PMID: 16647822]
[33]
national conference of state legislators state medical. marijuana laws 2020. available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx [accessed 12/18/2019]
[34]
Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the national survey of mental health and well-being. Soc Psychiatry Psychiatr Epidemiol 2001; 36(5): 219-27.
[http://dx.doi.org/10.1007/s001270170052] [PMID: 11515699]
[35]
Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82(17): 1556-63.
[http://dx.doi.org/10.1212/WNL.0000000000000363] [PMID: 24778283]
[36]
Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253.
[http://dx.doi.org/10.1136/bmj.38149.566979.AE] [PMID: 15258006]
[37]
Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29(2): 417-26.
[http://dx.doi.org/10.1038/sj.npp.1300340] [PMID: 14583744]
[38]
Zuardi AW, Crippa JA, Hallak JE, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 2012; 18(32): 5131-40.
[http://dx.doi.org/10.2174/138161212802884681] [PMID: 22716160]
[39]
Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35(3): 764-74.
[http://dx.doi.org/10.1038/npp.2009.184] [PMID: 19924114]
[40]
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the united states. Biol Psychiatry 2016; 79(7): 613-9.
[http://dx.doi.org/10.1016/j.biopsych.2016.01.004] [PMID: 26903403]
[41]
O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review epilepsy behav 2017; 70(part b): 341-8.
[http://dx.doi.org/10.1016/j.yebeh.2016.11.012]
[42]
u.s. food & drug administration (2019). fda regulation of cannabis and cannabis-derived products, including cannabidiol (cbd), 2019.Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulationcannabis-and-cannabis-derived-productsincludingcannabidiol-cbd.
[43]
Koubeissi M. Anticonvulsant effects of cannabidiol in Dravet Syndrome. Epilepsy Curr 2017; 17(5): 281-2.
[http://dx.doi.org/10.5698/1535-7597.17.5.281] [PMID: 29225539]
[44]
american psychiatric association. substance use disorders. diagnostic and statistical manual of mental disorders (5th ed) 2013.
[45]
Greene MC, Kelly JF. The prevalence of cannabis withdrawal and its influence on adolescents’ treatment response and outcomes: a 12-month prospective investigation. J Addict Med 2014; 8(5): 359-67.
[http://dx.doi.org/10.1097/ADM.0000000000000064] [PMID: 25100311]
[46]
Hines LA, Morley KI, Strang J, et al. Onset of opportunity to use cannabis and progression from opportunity to dependence: are influences consistent across transitions? Drug Alcohol Depend 2016; 160: 57-64.
[http://dx.doi.org/10.1016/j.drugalcdep.2015.12.032] [PMID: 26811121]
[47]
Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014; (12): CD008940.
[PMID: 25515775]
[48]
Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature am j addict 2007; 16(5): 331-42.
[http://dx.doi.org/10.1080/10550490701525665] [PMID: 17882603]

Rights & Permissions Print Cite
Article Metrics
12
2
1
© 2024 Bentham Science Publishers | Privacy Policy